Somatic mutations in cyclic AMP response element binding protein (CREBBP) and EP300, and removal or inactivation of the HAT coding domain affect approximately 39% of DLBCL patients [15], and are also associated with Rubinstein Tyabi Syndrome (RTS) [16,17]. This evidence concerns the gene CREBBP and diffuse large B-cell lymphoma.